No connection

Search Results

NVAX vs NVCR

NVAX
Novavax, Inc.
NEUTRAL
Price
$8.69
Market Cap
$1.42B
Sector
Healthcare
AI Confidence
75%
NVCR
NovoCure Limited
BEARISH
Price
$12.17
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
NVAX
3.25
NVCR
--
Forward P/E
NVAX
-8.57
NVCR
-10.44
P/B Ratio
NVAX
-11.06
NVCR
4.02
P/S Ratio
NVAX
1.26
NVCR
2.11
EV/EBITDA
NVAX
1.62
NVCR
-8.77

Profitability

Gross Margin
NVAX
63.52%
NVCR
74.8%
Operating Margin
NVAX
14.23%
NVCR
-21.33%
Profit Margin
NVAX
39.19%
NVCR
-20.79%
ROE
NVAX
--
NVCR
-38.89%
ROA
NVAX
25.72%
NVCR
-9.06%

Growth

Revenue Growth
NVAX
66.6%
NVCR
8.1%
Earnings Growth
NVAX
--
NVCR
--

Financial Health

Debt/Equity
NVAX
--
NVCR
0.73
Current Ratio
NVAX
2.13
NVCR
2.9
Quick Ratio
NVAX
1.83
NVCR
2.51

Dividends

Dividend Yield
NVAX
--
NVCR
--
Payout Ratio
NVAX
0.0%
NVCR
0.0%

AI Verdict

NVAX NEUTRAL

NVAX presents a complex profile with a stable Piotroski F-Score of 5/9, yet it exhibits severe fundamental contradictions. While the stock trades at a significant discount to its growth-based intrinsic value of $18.69 and shows impressive YoY revenue growth of 66.6%, the negative Price/Book ratio (-11.06) indicates a deficit in shareholders' equity. The transition from a low trailing P/E (3.25) to a negative forward P/E (-8.57) suggests that recent profitability may be transient. Combined with a completely bearish technical trend (0/100), the stock is a high-risk speculative play despite analyst 'buy' recommendations.

Strengths
Strong YoY revenue growth of 66.60%
Significant discount to intrinsic value ($8.69 vs $18.69)
Healthy short-term liquidity with a Current Ratio of 2.13
Risks
Negative shareholders' equity as indicated by Price/Book of -11.06
Negative forward P/E suggests a return to losses
Extreme historical earnings volatility with massive misses and beats
NVCR BEARISH

NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.

Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)

Compare Another Pair

NVAX vs NVCR: Head-to-Head Comparison

This page compares Novavax, Inc. (NVAX) and NovoCure Limited (NVCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile